Special Issue

New Insights in Antimicrobial Discovery

Message from the Guest Editors

Infectious diseases are a leading cause of morbidity and mortality, killing more than 14 million people globally every year. Furthermore, the emergence of antimicrobial resistance presents a significant threat to human and animal health despite advances in antimicrobial discovery. This Special Issue seeks manuscript submissions on all aspects of antimicrobial discovery, comprising nanotechnology, antimicrobial peptides, and modification of existent drugs in the quest to treat rising infectious diseases. All submission types, such as original research manuscripts, short communications, and reviews, are appreciated.

Guest Editors

Prof. Dr. Naveed Ahmed Khan

College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates

Prof. Dr. Ruqaiyyah Siddiqui

College of Arts and Sciences, American University of Sharjah, Sharjah 269999, United Arab Emirates

Deadline for manuscript submissions

closed (31 May 2023)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/101738

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

